Showing 201 - 220 results of 327 for search '(( 10 ((meet decrease) OR (((nn decrease) OR (mean decrease)))) ) OR ( 6 14 decrease ))*', query time: 0.15s Refine Results
  1. 201

    Global, regional, and national age-sex-specific burden of diarrhoeal diseases, their risk factors, and aetiologies, 1990–2021, for 204 countries and territories: a systematic analy... by Hmwe Hmwe, Kyu

    Published 2024
    “…The most pronounced decline was in children younger than 5 years, with a 79·2% (72·4–84·6) decrease in diarrhoeal deaths. Global YLLs also decreased substantially, from 186 million (147–221) in 1990 to 51·4 million (39·9–65·9) in 2021. …”
    Get full text
    Get full text
    Get full text
    article
  2. 202
  3. 203
  4. 204
  5. 205
  6. 206

    Dynamic stretching alone can impair slower velocity isokinetic performance of young male handball players for at least 24 hours by Haddad, Monoem

    Published 2019
    “…Two-way repeated measures ANOVAs revealed that 1) both the SS and control conditions exhibited knee extensor 60.s -1 (SS:-10.3%; p = 0.04, Control: -8.7%; p = 0.07) and 300.s -1 (SS: -12.9%; p = 0.005, Control: -16.3%; p = 0.02) isokinetic deficits at post-test, 2) DS impaired knee flexor 60.s -1 isokinetic work and power-related measures at post-test (Work: -10.1%; p = 0.0006; Power: -19.1%; p = 0.08) and at 24-hours' post-test (Work: 9.9%; p = 0.023; Power: -9.6%; p = 0.01), 3) DS (12.07% and 10.47%) and SS (13.7% and 14.6%) enhanced knee flexor 300.s -1 isokinetic force and power-related measures compared to control. …”
    Get full text
    Get full text
  7. 207
  8. 208
  9. 209
  10. 210
  11. 211
  12. 212
  13. 213
  14. 214
  15. 215

    The Expression of TBC1 Domain Family, Member 4 (TBC1D4) in Skeletal Muscles of Insulin-Resistant Mice in Response to Sulforaphane by Rizk, Nasser M

    Published 2020
    “…Results: SFN-treated DIO mice had significantly lower non-fasting blood glucose levels than vehicle-treated mice (194.16 ± 14.12 vs. 147.44 ± 20.31 mg/dL, vehicle vs. SFN, p value=0.0003). …”
    Get full text
    Get full text
  16. 216
  17. 217
  18. 218
  19. 219
  20. 220

    The Cardiovascular Benefits of Empagliflozin, A Sodium Glucose Cotransporter Inhibitor: Is NHE1 a Viable Target? by Al-Shamasi, Al-Anood

    Published 2020
    “…In this trial, treatment with EMPA over 2.6 years decreased cardiovascular vascular events (14% reduction). …”
    Get full text
    Get full text